StockData
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc. (ARQT) stock

ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30415% above fair value
$27.17−0.44 (-1.59%)

Close on Nov 19, 2026Market cap $3.42BP/E 123.5Yield –

Arcutis Biotherapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Arcutis Biotherapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $39.15M. For fiscal 2025 it was -$6.31M. The highest annual figure on record is -$6.31M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.31M–
FY2024Dec 31, 2024-$112.30M–
FY2023Dec 31, 2023-$247.49M–
FY2022Dec 31, 2022-$258.05M–
FY2021Dec 31, 2021-$175.62M–
FY2020Dec 31, 2020-$113.35M–
FY2019Dec 31, 2019-$43.13M–
FY2018Dec 31, 2018-$14.09M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.48M+4973.6%
Q1 FY2026Mar 31, 2026$2.24M–
Q4 FY2025Dec 31, 2025$26.19M–
Q3 FY2025Sep 30, 2025-$1.75M–
Q2 FY2025Jun 30, 2025$246.00K–
Q1 FY2025Mar 31, 2025-$30.99M–
Q4 FY2024Dec 31, 2024-$748.00K–
Q3 FY2024Sep 30, 2024-$34.83M–
Q2 FY2024Jun 30, 2024-$45.12M–
Q1 FY2024Mar 31, 2024-$31.60M–
Q4 FY2023Dec 31, 2023-$56.25M–
Q3 FY2023Sep 30, 2023-$44.05M–
Q2 FY2023Jun 30, 2023-$66.76M–
Q1 FY2023Mar 31, 2023-$80.43M–
Q4 FY2022Dec 31, 2022-$71.19M–
Q3 FY2022Sep 30, 2022-$67.70M–
Q2 FY2022Jun 30, 2022-$62.06M–
Q1 FY2022Mar 31, 2022-$57.10M–
Q4 FY2021Dec 31, 2021-$51.97M–
Q3 FY2021Sep 30, 2021-$41.02M–
Q2 FY2021Jun 30, 2021-$35.87M–
Q1 FY2021Mar 31, 2021-$46.76M–
Q4 FY2020Dec 31, 2020-$32.72M–
Q3 FY2020Sep 30, 2020-$33.80M–
Q2 FY2020Jun 30, 2020-$25.78M–
Q1 FY2020Mar 31, 2020-$21.05M–
Q4 FY2019Dec 31, 2019-$16.86M–
Q3 FY2019Sep 30, 2019-$10.73M–
Q2 FY2019Jun 30, 2019-$8.29M–
Q1 FY2019Mar 31, 2019-$7.26M–

More Arcutis Biotherapeutics figures

See a number that looks wrong?